A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Trial Profile

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs LY 3023414 (Primary) ; Cisplatin; Fulvestrant; Midazolam; Pemetrexed
  • Indications Advanced breast cancer; Cancer; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 4 Mar 2017 to 1 Oct 2020.
    • 22 Jun 2017 Planned primary completion date changed from 4 Mar 2017 to 1 May 2018.
    • 02 Jun 2017 Results (n=9) assessing safety and preliminary activity of LY-3023414 in combination with fulvestrant (F) for breast cancer patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top